Ben-Menachem E, Persson L, Mumford J
Department of Neurology, University of Göteborg, Sahlgren Hospital, Sweden.
Epilepsy Res. 1990 Apr;5(3):240-6. doi: 10.1016/0920-1211(90)90045-w.
The purpose of this study was to evaluate on an open basis the long-term efficacy and safety of vigabatrin in drug-resistant partial epilepsy as add-on therapy, administered on a once daily basis. Thirty-five patients entered the study. Twenty patients (57%) responded to therapy and are still on drug. This efficacy is in agreement with that seen in double-blind controlled studies on twice daily dose schedules. There did not appear to be any loss of efficacy with continued treatment at this dose regimen in patients responding favourably to the drug. The once daily dosing schedule was well tolerated and side effects were usually mild and always reversible. Vigabatrin seems to be a valuable therapeutic addition for patients with partial seizures resistant to standard anti-epileptic drugs.
本研究的目的是在开放基础上评估氨己烯酸作为附加疗法每日一次给药用于耐药性部分性癫痫的长期疗效和安全性。35名患者进入该研究。20名患者（57%）对治疗有反应且仍在服药。该疗效与每日两次给药方案的双盲对照研究中所见的疗效一致。在对该药反应良好的患者中，以该剂量方案持续治疗未出现疗效丧失的情况。每日一次给药方案耐受性良好，副作用通常较轻且总是可逆的。对于对标准抗癫痫药物耐药的部分性癫痫发作患者，氨己烯酸似乎是一种有价值的治疗补充药物。
